Ashland renews €125M receivables facility while carrying waived defaults

Ashland is a specialty ingredients company focused on life sciences, personal care and specialty additives, using portfolio pruning, innovation and cash-flow generation to improve margins and fund growth. Its latest reported quarter showed broad volume growth, but lower Specialty Additives and Intermediates earnings still pressured profitability.

The financing remains available, not expanded. Ashland amended and restated its cross-border receivables securitization documents, preserving a facility limit of €125 million, with dollar and sterling sublimits also specified in the definitions schedule (Schedule 1—Master Definitions Schedule). Bank of America, N.A. is transferring its committed-purchaser role to Bank of America Europe DAC, while the core borrowing structure, collateral package and performance guarantee remain in place. 〔0〕

The buried signal is that this is not a clean refinancing. The amended agreement confirms that no termination event exists except for a “Specified Default” and an “Anticipated Default” identified in a March 12, 2026 limited waiver; the filing does not explain the underlying breach or quantify its financial impact (Deed of Amendment and Restatement, Section 4.1). 〔1〕

The amendment buys continuity, not a clean bill of health. It keeps Ashland’s working-capital funding operational through September 21, 2029 and maintains the 5% subordinated retention requirement, but it also preserves tight protections around receivable quality, dilution, delinquency and financial-covenant breaches (Schedule 1—Master Definitions Schedule; Receivables Purchase Agreement, Sections 5.02 and 7.01). The lender change itself is administrative; the meaningful new information is that the previously waived credit issue remains embedded in the facility documents.

Bottom line: Ashland has preserved an important liquidity channel, but the filing confirms that lenders are still accommodating a known credit problem rather than simply renewing routine funding. The business impact is manageable for now, but the waiver—not the bank transfer—is the material signal.